指南与共识湿疹皮炎与荨麻疹

HOME VII 共识:特应性湿疹试验核心结局工具推荐

Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
指南 / 共识 · Br J Dermatol · 2020-11-11

HOME VII 共识会议于2019年在东京召开,74名来自16国的参会者通过证据汇报、讨论和匿名投票,为特应性湿疹试验的生活质量、长期控制和瘙痒强度域确定了核心结局工具。共识推荐成人用DLQI、儿童用CDLQI、婴儿用IDQoL,长期控制用RECAP或ADCT,瘙痒峰值用NRS-11。

要点

  • 生活质量:成人用DLQI,儿童用CDLQI,婴儿用IDQoL。
  • 长期控制:RECAP或ADCT,数据收集频率未达共识。
  • 瘙痒强度:NRS-11(过去24小时峰值)用于年长儿童和成人。

核心结论

  • 特应性湿疹临床试验的核心结局集已完整,新试验和系统评价应使用指定的域和工具。

研究设计与样本

  • 面对面共识会议于2019年4月8-10日在日本东京举行,74名参会者(47名医疗专业人员/方法学家、14名患者、13名行业代表),来自16个国家。
  • 共识决策通过证据报告、全体和小型小组讨论以及匿名投票做出,使用预设共识规则。

主要发现

  • 共识同意生活质量应使用DLQI测量成人、CDLQI测量儿童、IDQoL测量婴儿。
  • 长期控制应使用RECAP或ADCT工具。
  • 未就长期控制的数据收集频率达成共识。
  • 推荐NRS-11(过去24小时峰值瘙痒)作为年长儿童和成人试验中症状域的附加工具。
  • 同意所有核心结局工具至少在基线和主要结局评估时采集。

关键数值与推荐

  • 生活质量:成人DLQI,儿童CDLQI,婴儿IDQoL。
  • 长期控制:RECAP或ADCT。
  • 瘙痒强度:NRS-11(过去24小时峰值)用于年长儿童和成人试验。
  • 所有核心结局工具至少在基线和主要结局评估时采集。

临床怎么用

  • 在所有新的特应性湿疹临床试验和系统评价中,使用共识指定的域和工具。
  • 根据年龄选择生活质量工具:成人DLQI、儿童CDLQI、婴儿IDQoL。
  • 长期控制使用RECAP或ADCT,但数据收集频率需根据试验设计决定。
  • 年长儿童和成人试验中,将NRS-11作为瘙痒强度的附加工具。
  • 确保在基线和主要结局评估时采集所有核心结局工具。

局限性

  • 未就长期控制的数据收集频率达成共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema clinical trials. Previous consensus meetings have agreed upon preferred instruments for clinician-reported signs (Eczema Area and Severity Index - EASI) and patient-reported symptoms (Patient-Oriented Eczema Measure - POEM). This paper reports consensus decisions from the HOME VII meeting. OBJECTIVE: To complete the core outcome set for atopic eczema by agreeing upon core outcome instruments for the domains of quality of life, long-term control and itch intensity. METHODS: Face-to-face consensus meeting held in Tokyo, Japan (8th to 10th April, 2019) including 74 participants (47 healthcare professionals/methodologists, 14 patients, 13 industry representatives), from 16 countries. Consensus decisions were made by presentations of evidence, followed by whole and small group discussions and anonymous voting using pre-defined consensus rules. RESULTS: It was agreed by consensus that quality of life should be measured using the Dermatology Life Quality Index (DLQI) for adults, the Children's Dermatology Life Quality Index (CDLQI) for children, and the Infant's Dermatology Quality of Life Index (IDQoL) for infants. For long-term control, the Recap of Atopic Eczema (RECAP) instrument or the Atopic Dermatitis Control Test (ADCT) should be used. Consensus was not reached over the frequency of data collection for long-term control. The peak itch numerical rating scale(NRS)-11 past 24 hours was recommended as an additional instrument for the symptom domain in trials of older children and adults. Agreement was reached that all core outcome instruments should be captured at baseline and at the time of primary outcome assessment as a minimum. CONCLUSIONS: For now, the core outcome set for clinical trials in atopic eczema is complete. The specified domains and instruments should be used in all new clinical trials and systematic reviews of eczema treatments.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Thomas KS, Apfelbacher CA, Chalmers JR, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Br J Dermatol. 2020. PMID: 33179283. doi:10.1111/bjd.19673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。